deltatrials
Active Not Recruiting PHASE2 INTERVENTIONAL 3-arm NCT02949284

Androgen Receptor Antagonist ARN-509 With or Without Abiraterone Acetate, Gonadotropin-Releasing Hormone Analog, and Prednisone in Treating Patients With High-Risk Prostate Cancer Undergoing Surgery

Randomized Three-Arm Trial to Evaluate the Effect of Neoadjuvant Apalutamide Alone or in Combination With Abiraterone Acetate and GnRH Agonist on Enhancing Surgical Outcome of Nerve-Sparing Radical Prostatectomy in Men With High-Risk Prostate Cancer

Sponsor: National Cancer Institute (NCI)

Conditions Stage II Prostate Adenocarcinoma Stage III Prostate Adenocarcinoma
Interventions Abiraterone Acetate Androgen Receptor Antagonist ARN-509 Gonadotropin-releasing Hormone Analog Prednisone Quality-of-Life Assessment Questionnaire Administration Radical Prostatectomy
Updated 19 times since 2017 Last updated: Jan 5, 2026 Started: Jun 20, 2017 Primary completion: Jun 30, 2026 Completion: Jun 30, 2027
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT02949284, this PHASE2 trial focuses on Stage II Prostate Adenocarcinoma and Stage III Prostate Adenocarcinoma and remains ongoing. Sponsored by National Cancer Institute (NCI), it has been updated 19 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Jul 2017 · 5 months · monthly snapshot~Jul 2017 – ~Jun 2018 · 11 months · monthly snapshot~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshot~Jul 2018 – ~Mar 2019 · 8 months · monthly snapshot~Mar 2019 – ~Apr 2020 · 13 months · monthly snapshot~Apr 2020 – ~Oct 2020 · 6 months · monthly snapshot~Oct 2020 – ~Jan 2021 · 3 months · monthly snapshot~Jan 2021 – ~Apr 2021 · 3 months · monthly snapshot~Apr 2021 – ~May 2021 · 30 days · monthly snapshot~May 2021 – ~Jun 2022 · 13 months · monthly snapshot~Jun 2022 – ~Dec 2022 · 6 months · monthly snapshot~Dec 2022 – ~May 2023 · 5 months · monthly snapshot~May 2023 – ~Oct 2023 · 5 months · monthly snapshot~Oct 2023 – ~Jul 2024 · 9 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Mar 2025 · 6 months · monthly snapshot~Mar 2025 – ~Feb 2026 · 11 months · monthly snapshot~Feb 2026 – present · 5 months · monthly snapshot

Change History

19 versions recorded

  1. Feb 2026 — Present [monthly]

    Active Not Recruiting PHASE2

  2. Mar 2025 — Feb 2026 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  3. Sep 2024 — Mar 2025 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Oct 2023 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 14 earlier versions

  1. May 2023 — Oct 2023 [monthly]

    Recruiting PHASE2

  2. Dec 2022 — May 2023 [monthly]

    Recruiting PHASE2

  3. Jun 2022 — Dec 2022 [monthly]

    Recruiting PHASE2

  4. May 2021 — Jun 2022 [monthly]

    Recruiting PHASE2

  5. Apr 2021 — May 2021 [monthly]

    Recruiting PHASE2

  6. Jan 2021 — Apr 2021 [monthly]

    Recruiting PHASE2

  7. Oct 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  8. Apr 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  9. Mar 2019 — Apr 2020 [monthly]

    Recruiting PHASE2

  10. Jul 2018 — Mar 2019 [monthly]

    Recruiting PHASE2

  11. Jun 2018 — Jul 2018 [monthly]

    Recruiting PHASE2

  12. Jul 2017 — Jun 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  13. Feb 2017 — Jul 2017 [monthly]

    Not Yet Recruiting PHASE2

  14. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Rutgers, The State University of New Jersey
Data source: Rutgers, The State University of New Jersey

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations